Huapont Life SciencesLtd Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Hai An Zhang

Algemeen directeur

CN¥1.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Huapont Life SciencesLtd (SZSE:002004) Might Be Having Difficulty Using Its Capital Effectively

Jun 04

Investors Can Find Comfort In Huapont Life SciencesLtd's (SZSE:002004) Earnings Quality

May 03

Is Huapont Life SciencesLtd (SZSE:002004) A Risky Investment?

Mar 25

CEO

Hai An Zhang (43 yo)

6.1yrs

Tenure

CN¥1,702,600

Compensatie

Mr. Hai An Zhang serves as General Manager since October 29, 2018 & Director since November 16, 2018 at Huapont Life Sciences Co.,Ltd.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hai An Zhang	GM & Director	6yrs	CN¥1.70m	geen gegevens
Rong Wang	Director	12.8yrs	CN¥1.88m	0.55% CN¥ 49.5m
Zhonghai Liu	Independent Director	3.3yrs	CN¥142.90k	geen gegevens
Qiang Bian	Shareholder Supervisor	13.2yrs	CN¥96.00k	geen gegevens
Wen Wang	Employee Representative to the Board for Supervisors	9.2yrs	geen gegevens	geen gegevens
Ming Li	Independent Director	3.3yrs	CN¥142.90k	geen gegevens
Zhengjun Wang	Chairman of the Supervisory Board	3.3yrs	geen gegevens	0.010% CN¥ 929.8k

6.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002004 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

Huapont Life SciencesLtd Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Huapont Life Sciences Co., Ltd., Annual General Meeting, Apr 12, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023)

Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 20%

Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023)

Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024

Huapont Life SciencesLtd (SZSE:002004) Might Be Having Difficulty Using Its Capital Effectively

Dividend of CN¥0.22 announced

Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024

Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023

Investors Can Find Comfort In Huapont Life SciencesLtd's (SZSE:002004) Earnings Quality

Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023)

Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Is Huapont Life SciencesLtd (SZSE:002004) A Risky Investment?

Investor sentiment improves as stock rises 15%

Huapont Life Sciences Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Less than half of directors are independent

Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022)

Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023

Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021)

Investor sentiment improved over the past week

Huapont Life Sciences Co., Ltd. Announces Dividend on A Shares for the Year 2021, Payable on June 2, 2022

First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021)

Less than half of directors are independent

Huapont Life Sciences Co., Ltd. Approves Profit Distribution for 2021

Huapont Life Sciences Co., Ltd., Annual General Meeting, Apr 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Zhejiang Xinan Chemical Industrial Group Co.,Ltd (SHSE:600596) entered into an agreement to acquire 12.31% stake in Nutrichem Company Limited from Huapont Life Sciences Co., Ltd. (SZSE:002004) for approximately CNY 800 million.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)

Huapont Life Sciences Co., Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day low: CN¥5.02

New 90-day high: CN¥6.06

New 90-day high: CN¥5.71

Third quarter earnings released

New 90-day low: CN¥5.18

Earnings released

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd